TIMP2 Recombinant Rabbit mAb (SDT-3369-4)

Tissue Inhibitor of Metalloproteinases-2 (TIMP2) has emerged as a critical diagnostic biomarker, particularly for Acute Kidney Injury (AKI). Unlike traditional markers like serum creatinine, which rise only after significant renal damage has occurred, TIMP2 levels increase rapidly in urine within hours of cellular stress, enabling early detection before functional decline. Clinically, TIMP2 is often measured in combination with IGFBP7 (as the product [TIMP-2]·[IGFBP7]) to predict moderate-to-severe AKI in critically ill patients, such as those post-cardiac surgery or with sepsis. This test provides a crucial window for early intervention, potentially preventing irreversible kidney damage and reducing mortality.

Beyond nephrology, TIMP2 holds diagnostic value in oncology. As a regulator of matrix metalloproteinases (MMPs), its expression levels correlate with tumor progression, metastasis potential, and patient prognosis in various cancers, including breast, ovarian, and gastric carcinomas. Elevated or suppressed TIMP2 levels can help stratify patient risk and guide therapeutic decisions. Furthermore, emerging research suggests TIMP2’s role in monitoring the transition from acute injury to chronic fibrosis, making it a versatile tool for tracking disease progression. Its ability to be detected in non-invasive samples like urine or blood enhances its clinical utility, offering a cost-effective, sensitive, and specific option for early diagnosis and dynamic monitoring across multiple pathological conditions.